Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

Supernus Pharmaceuticals’s 18.3% return over the past six months has outpaced the S&P 500 by 12.3%, and its stock price has climbed to $50.84 per share. This performance may have investors wondering...

3 Reasons to Avoid SUPN and 1 Stock to Buy Instead

February 16, 2026

Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026

Topics Stocks Supply Chain

February 12, 2026

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

1 Cash-Heavy Stock on Our Buy List and 2 We Brush Off

February 08, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but...

1 Healthcare Stock to Consider Right Now and 2 We Brush Off

January 28, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Topics Stocks

2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds

January 25, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

3 Unprofitable Stocks We Steer Clear Of

January 21, 2026

As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric...

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution

January 01, 2026

Via MarketMinute

3 Low-Volatility Stocks We’re Skeptical Of

December 31, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

3 of Wall Street’s Favorite Stocks That Concern Us

December 22, 2025

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗

December 19, 2025

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.

Via Stocktwits

Topics Cannabis ETFs Government

Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back ↗

December 15, 2025

The sale hints at profit-taking in a stock that’s executing operationally but facing tougher questions about durability and valuation.

Via The Motley Fool

Topics Regulatory Compliance

1 Cash-Heavy Stock for Long-Term Investors and 2 We Turn Down

December 14, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

3 Stocks Under $50 That Concern Us

December 11, 2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

3 Unprofitable Stocks We Find Risky

December 03, 2025

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

December 03, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 14.4% over...

1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds

November 23, 2025

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

Topics Stocks

November 21, 2025

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

November 21, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Supernus Pharmaceuticals (NASDAQ:SUPN) and...

A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.

Topics Artificial Intelligence Intellectual Property

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗

November 18, 2025

Via The Motley Fool

Topics Regulatory Compliance

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗

November 18, 2025

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

Via The Motley Fool

3 Russell 2000 Stocks Walking a Fine Line

November 13, 2025

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher...

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London

November 12, 2025

Supernus Pharmaceuticals reported Q3 results that were above Wall Street’s revenue and profit expectations, but the market reacted negatively, reflecting concerns over execution challenges and forward...

5 Must-Read Analyst Questions From Supernus Pharmaceuticals’s Q3 Earnings Call

November 11, 2025

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 16.8% in the morning session after the company's third-quarter 2025 earnings report, as a weak full-year forecast...

Topics Earnings

Why Supernus Pharmaceuticals (SUPN) Shares Are Trading Lower Today

November 05, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 CY2025, with sales up 9.3% year on year to $192.1 million. On the other hand, the...

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 05, 2025

Via Benzinga

SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs

November 05, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.3% year on year to $192.1 million. On the...

Topics Supply Chain

Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3

November 04, 2025

Supernus Announces Third Quarter 2025 Financial Results

November 04, 2025